Sulfur mustard injured patients.
Conditions
Interventions
Azithromycin 250 mg daily.
Azithromycin 250 mg daily
Sponsors
Janbazan Medical and Engineering Research Center
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Documented exposure to single high dose of sulfur mustard (SM) gas. 2- Documented chronic pulmonary disease caused by SM by HRCT. 3- Patients' will to enter the study. Exclusion criteria: 1-having pneumonia and/or acute bronchitis; 2-smoking cigarettes or being a substance abuser; 3-having any illnesses in which the medications could not be stopped; 4-occurrence of any severe side effects of macrolides (headache, GI upset, fever, skin rash, abdominal dicomfort, diarrhea, gray feces, icter, eosinophilia, stridor, acute cholestatic hepatitis, pruritus, dark urine, osteomatitis, depression, fatigue, dysphagia, glossitis, dizziness, bahavioral changes); 5-using any kind of antioxidant drugs; 6-deterioration of clinical conditions during the course of the study. 7- Simultanous use of following drugs: Terfenadine, teophyline or its analogues, carbamazepin, ergotamin, anticoagulants like warfarin, cisapride, digoxin, triazolam, phenytoin, corticosteroids (prednisolone over 10mg/day), immunosupressives, systemic antibiotics. 8- illiterate patient, 9-exacerbation of disease in the last month, 10-abnormal serum creatinine, ALT, AST, total bilirubin > 2x normal 11-not using at least 80% of the drugs in the course of the trial.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough. Timepoint: 3 months and 6 months from begining of the trial and 3 months follow up. Method of measurement: History.;Dyspnea. Timepoint: 3 months and 6 months from begining of the trial and 3 months follow up. Method of measurement: History.;Sputum. Timepoint: 3 months and 6 months from begining of the trial and 3 months follow up. Method of measurement: History.;Hemoptysis. Timepoint: 3 months and 6 months from begining of the trial and 3 months follow up. Method of measurement: History.;Lung Function (FEV1, FVC, FEV1/FVC). Timepoint: 3 months and 6 months from begining of the trial and 3 months follow up. Method of measurement: Spirometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Yunes Panahi
chemical iinjuries research center, Baqiyatallah university of medical sciences
Outcome results
None listed